Get the Stockscreener App
0.592
3.66%
-0.036
Cel-Sci Corp. stock is traded at $0.592, with a volume of 122.28K.
It is down -3.66% in the last 24 hours and down -32.78% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$0.628
Open:
$0.6192
24h Volume:
122.28K
Relative Volume:
0.36
Market Cap:
$41.16M
Revenue:
-
Net Income/Loss:
$-32.37M
P/E Ratio:
-0.7688
EPS:
-0.77
Net Cash Flow:
$-23.22M
1W Performance:
+8.02%
1M Performance:
-32.78%
6M Performance:
-53.82%
1Y Performance:
-75.60%
1-Day Range:
$0.5911
$0.63
1-Week Range:
$0.55
$0.6499
52-Week Range:
$0.5402
$3.23
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CVM | 0.601 | 41.16M | 0 | -32.37M | -23.22M | -0.77 |
| VRTX | 449.28 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.98 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.38 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.29 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.94 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
StockNews.com Upgrades CEL-SCI (NYSE:CVM) to “Hold” - Defense World
CVM stock touches 52-week low at $0.68 amid sharp annual decline - Investing.com India
CEL-SCI, FDA agree on Multikine trial design (CVM:NYSE) - Seeking Alpha
FDA agrees with CEL-SCI's patient selection for cancer study - Investing.com
3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity Conference - Investing.com
3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity Conference - Investing.com
CEL-SCI (FRA:LSRM) Free Cash Flow : €-17.72 Mil (TTM As of Jun. 2024) - GuruFocus.com
CVM stock touches 52-week low at $0.87 amid market challenges - Investing.com Australia
CVM stock touches 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa
FDA panel challenges PD-L1 inhibitors, CEL-SCI's Multikine shows promise - Investing.com
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients - Yahoo Finance
Conestoga Capital Advisors Sold National Research Corp. (NRC), as it Fell Short of Expectations - Yahoo Finance UK
CVM stock touches 52-week low at $0.93 amid market challenges - Investing.com India
Exploring Opportunities in the Therapeutic Vaccines Market: - openPR
CVM stock touches 52-week low at $1.01 amid market challenges - Investing.com India
CEL-SCI (NYSE:CVM) Trading Down 3.8%Here's What Happened - MarketBeat
SEC Form POS AM filed by Cel-Sci Corporation - Quantisnow
A company insider recently sold 10,000 shares of Akero Therapeutics Inc [AKRO]. Should You Sale? - Knox Daily
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine - Business Wire
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer - Yahoo Finance
Annaly Capital Management Inc [NLY] CEO and CIO makes an insider purchase of 50,000 shares worth 1.0 million. - Knox Daily
CVM Stock Sees Decline of Approximately -6.25% in Last Five Days - Knox Daily
How to interpret Cel-Sci Corp. (CVM)’s stock chart patterns - US Post News
Cel-Sci Corp.’s Market Journey: Closing Weak at 1.05, Down -1.87 - The Dwinnex
Healthcare Stock Performance - Yahoo Finance
CEL-SCI Co. (NYSE:CVM) Position Raised by Thoroughbred Financial Services LLC - Defense World
Celonis expands alliance with Samsung for process optimisation - Yahoo! Voices
Stifel Upgrades Celestica Inc. (CLS) to Buy from Hold - Insider Monkey
Creo Sells Stake of Subsidiary to Chinese Market-Leader - Business News Wales
Celonis Expands Partnership with Samsung Fire & Marine Insurance to Optimize Processes and to Drive Value - Business Wire
Check out these key findings about Complete Solaria Inc. (CSLR) - SETE News
Trend Tracker for (CLS) - Stock Traders Daily
Creo Medical to get £25m boost from majority sale of its European business - Business Live
Medical device company to sell stake of subsidiary to Chinese manufacturerequity value of €72m - Insider Media
Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks
Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat
Investing in Complete Solaria Inc. (CSLR) Is Getting More Attractive - Knox Daily
CVM’s Market Flip-Flop: Exploring the Volatility of 2023 Performance - The InvestChronicle
Exact Sciences Debuts Positive Topline Results for Trial of Blood-Based Colorectal Cancer Screening Algorithm - Patient Care Online
Potential Price Increase for Cel-Sci Corp. (CVM) After Recent Insider Activity - Knox Daily
ESMO: Exact Sciences shows off early colorectal cancer blood test data - Fierce Biotech
Multikine shows promise in head and neck cancer study - Investing.com
Healthy Upside Potential: Celestica, Inc. (CLS) - SETE News
ESMO 2024: Exact Sciences unveils results from cancer algorithm trial - Medical Device Network
CEL-SCI Corp's (CVM) Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - StreetInsider.com
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation – Company AnnouncementFT.com - Financial Times
Exact Sciences announces data for CRC screening test - TipRanks
Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - Yahoo Finance
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024 - Business Wire
Celestica Inc. (CLS): Among the Worst Performing AI Stocks of Previous Week - Insider Monkey
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):